View printer-friendly version |
« Back |
June 14, 2004 5:07 p.m. |
![]() |
Teva And Active Biotech Announce Agreement For Laquinimod Potential Oral Therapy For Multiple Sclerosis |
![]() |
![]() |
Jerusalem, Israel, and Lund, Sweden, June 14, 2004 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) and Active Biotech AB (Stockholm: ACTI.ST) announced today that they have signed an agreement to develop and commercialize laquinimod, Active Biotech's novel immunomodulatory compound, which has the potential to be an orally available disease modifying treatment of multiple sclerosis (MS).
|